Vnitr Lek 2013, 59(6):482-485

Adherence and persistence with a focus on the treatment of hypertensive patients

M. Souček
II. interní klinika Lékařské fakulty MU a FN u sv. Anny v Brně, přednosta prof. MUDr. Miroslav Souček, CSc.

Insufficient adherence of patients to treatment is a serious problem and it is monitored most frequently in hypertensive patients. The possibilities of increasing adherence to long-term treatment include mainly the motivation and education of patients, simple dosage regimes, telephone consultations and involving the patient in the treatment process (self-monitoring), but it also means providing information about the consequences of failure to adhere to the treatment process. Other possibilities can include new dosage forms which increase the biological availability of medicines, reduce the variability of absorption, and thus allow for achieving their more stable levels. It is possible to take advantage of fixed combinations which can improve adherence. Some new dosage forms simplify the therapy for patients and make it more pleasant. One of the latest innovations is for example, orodispersible dosage forms, which have been recently introduced in the therapy of arterial hypertension. In order to improve the adherence of patients to hypertension treatment it is necessary to use all means available adjusted to the individual needs of patients.

Keywords: adherence; persistence; hypertension; orodispersible tablets

Received: April 29, 2013; Published: June 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M. Adherence and persistence with a focus on the treatment of hypertensive patients. Vnitr Lek. 2013;59(6):482-485.
Download citation

References

  1. Vrablík M. Adherence k léčbě hypertenze: pomohou nové lékové formy? Intern Med Prax 2012; 14: 415-418.
  2. International Society for Pharmacoeconomics - Outcomes Research. Available from: http://www.ispor.org/sigs/mcp_accomplisment.asp.
  3. Motlová L, Holub D. Compliance a adherence: spolupráce při léčbě. Remedia 2005; 15: 514-516.
  4. Baptista LE. Predictors of persistence with antihypertensive therapy. Results from the NHANES. Am J Hypertens 2008; 21: 183-188. Go to original source... Go to PubMed...
  5. Cheng JW, Kalis MM, Feifer S. Patient-reported adherence to guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Pharmacotherapy 2001; 21: 828-841. Go to original source... Go to PubMed...
  6. Toverund EL, Roise AK, Hogstad G et al. Norwegian patients on generic antihypertensive drugs: a qualitative study of their own experiences. Eur J Clin Pharmacol 2011; 67: 33-38. Go to original source... Go to PubMed...
  7. Iqbal M, Khuroo A, Batolar LS et al. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers. Clin Ther 2010; 32: 588-596. Go to original source... Go to PubMed...
  8. Angeli DG, Trezza C. Quality and stability of ramipril generics/copies versus reference ramipril (Tritace): a 3-month stability comparative study. Clin Drug Investig 2009; 29: 667-676. Go to original source... Go to PubMed...
  9. Monane M, Bohn RL, Gurwitz JH et al. The effects of initial drugchoice and comorbidity on antihypertenxysive therapy compliance: results from a population-basid study in the elderly. Am Hypertens 1997; 10: 697-704. Go to original source... Go to PubMed...
  10. Monane M, Bohn RL, Gurwitz JH et al. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health 1996; 86: 1805-1808. Go to original source... Go to PubMed...
  11. Van Wijk BL, Klungel OH, Heerdink ER. Rate and determinants of 10-years persistence with antihypertensive drugs. J Hypertens 2005; 23: 2101-2107. Go to original source... Go to PubMed...
  12. Bautista LE. Predictors of Persistence With Antihypertensive Therapy: Results From the NHANES. Am J Hypertens 2008; 21: 183-188. Go to original source... Go to PubMed...
  13. Speirs C, Wagniart F, Poggi L. Perindopril post marketing surveillance: a 12 month study in 47 351 hypertensive patients. Br J Clin Pharmacol 1998; 46: 63-70. Go to original source... Go to PubMed...
  14. Registration file for Prestarium Neo Orodispersible.
  15. Zkrácená informace o přípravku Prestarium NEO/NEO FORTE ORODISPERZNÍ tablety.
  16. Salvetti A. Newer ACE inhibitors: a look at the future. Drug 1990; 40: 800-828. Go to original source... Go to PubMed...
  17. McAreavey D, Robertson JI. ACE inhibitors and moderate hypertension. Drug 1990; 10: 326-345. Go to original source... Go to PubMed...
  18. Limura O, Shimamotok K. Role of kallikrein-kinin systém in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension. J Cardiovasc Pharmacol 1989; 13 (Suppl 3): S63-S66. Go to original source... Go to PubMed...
  19. Gainer JV, Morrow JD, Loveland A et al. Effect of bradykinin receptor blockade on the response to angiotensin converting-enzyme inhibitors in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285-1292. Go to original source... Go to PubMed...
  20. Ceconi C, Francolini G, Olivares A et al. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007; 577: 1-6. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.